Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis
about
The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalizationTumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitisCCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritisThe Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid ArthritisCross-desensitization of CCR1, but not CCR2, following activation of the formyl peptide receptor FPR1.Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.Targeting of CCL2-CCR2-Glycosaminoglycan Axis Using a CCL2 Decoy Protein Attenuates Metastasis through Inhibition of Tumor Cell Seeding.Effects of interleukin-1β and tumor necrosis factor-α on macrophage inflammatory protein-3α production in synovial fibroblast-like cells from human temporomandibular jointsGene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012.Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4.Identifying key genes in rheumatoid arthritis by weighted gene co-expression network analysis.T cell specific Cxcr5 deficiency prevents rheumatoid arthritis.Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review.Recommendations for the development and validation of flow cytometry-based receptor occupancy assays.Successes and failures of chemokine-pathway targeting in rheumatoid arthritis.Macrophage heterogeneity in the context of rheumatoid arthritis.IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease.The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites.What is the future of CCR5 antagonists in rheumatoid arthritis?Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1.Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis.CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis.Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases.Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial.Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis.European League against rheumatism - selected presentation and poster a highlights June 11th to 13th 2013.CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis.T Cells That Help B Cells in Chronically Inflamed Tissues
P2860
Q24337078-DFF3529D-1D51-40B7-BE31-2181BD28A1F8Q24633598-DFFF5D9C-6B2C-43C1-8B44-BE9D2827020DQ24701793-45892460-0318-4204-8C12-EAE1A842A85DQ26774681-8C4B758A-D041-4E68-8A71-F0AC3578B48AQ33672477-D3332415-46BE-4AC2-8155-301BD397F25DQ33805455-FEEE5915-5DBC-4ABB-83EE-B4F680812302Q36527922-0E646C17-790C-4C85-8198-08E8AFB8D3D1Q37261899-84F93C43-71A9-47B7-9315-2F0C1F69EAD3Q37331952-38483133-609C-4BB1-A009-E98EA0D63E90Q37432097-2B88D5AA-65C9-44BE-A059-2CDDB3B92F82Q38083321-F8E9EA1C-567B-49E7-98CF-3861F1B46989Q38196934-A3ABF286-56BD-46B8-93FD-AD667B6EA149Q38434343-D36E365B-9D1B-4BCB-8562-E03B9427C50CQ38615369-E2C9F399-9B9B-4791-80C1-0BCF050DFF35Q38618883-6761BBA5-7BBF-4ADE-8657-4FBDFB1F23CCQ38632834-301C72F3-912E-4423-A396-70925D79E8F8Q38647749-25D1C2A6-D0AA-4168-B399-0B35DA9EB455Q38844780-AF2D41B7-33C1-4E09-9D5A-E64776504C1FQ39619506-E18D9A9D-26E3-4131-9EB4-B4FD823FB2F7Q41945153-36B1ED7F-B155-4D2B-9E20-8850ADE4444CQ42326321-079DD28B-6AB6-47CD-A134-A5593AFC9363Q43239473-BDBA9FAA-BA92-4F31-929C-6B6DDA56E75FQ45950376-CF94E45B-1DC7-4B57-8F10-054B670D5AFDQ47113676-11C28EE3-E67B-41A6-9666-6FA6F72994A9Q48129259-60ED032B-89B0-43A7-94DC-0237C5CA052FQ48268499-E6DDCB40-9796-47FF-89C4-3566A76C1327Q48297258-CAA93C12-A3C8-4B4F-9C28-F055419FE802Q53309302-FFEFA0E4-16CF-42B5-AA57-B488FD32F0D9Q54170357-9A553D55-1358-41D2-AE7E-72E246B847B3Q58712847-D4B87E17-EB38-49A6-A4C8-05E076E29786
P2860
Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@ast
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@en
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@nl
type
label
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@ast
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@en
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@nl
prefLabel
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@ast
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@en
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@nl
P2093
P2860
P1433
P1476
Why CCR2 and CCR5 blockade fai ...... atment of rheumatoid arthritis
@en
P2093
Clarissa E Vergunst
Ivy Y K Choi
Kris A Reedquist
Maria C Lebre
Paul P Tak
Richard Horuk
Saïda Aarrass
P2860
P304
P356
10.1371/JOURNAL.PONE.0021772
P407
P577
2011-07-01T00:00:00Z